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Polyclonal antibodies have been raised to synthetic amino acid sequences of th  bovine GABAA receptor ~1 and % sub- 
units. Anti-~l subunit antibodies recognise a polypeptide of 53 kDa whereas anti-% subunit antibodies recognise a poly- 
peptide of 59-60 kDa, in Western blots of GABA^ receptor purified from adult bovine cerebral cortex, cerebellum and 
12-day calf cerebral cortex. 
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1. INTRODUCTION 
7-Aminobutyric acid (GABA) is the major in- 
hibitory neurotransmitter in the mammalian cen- 
tral nervous ystem. It mediates its effects by the 
specific interaction with the GABAA receptor 
which is a ligand-gated CI- channel. The receptor 
is a complex multi-subunit protein which possesses 
aUosteric binding sites for the anxiolytic ben- 
zodiazepines, the barbiturate drugs and a group of 
compounds called collectively the chloride channel 
ligands which include the convulsant compounds t- 
butylbicyclophosphorothionate (TBPS) and picro- 
toxin [1]. The GABAA receptor has been purified 
to apparent homogeneity from several vertebrate 
species and it has been shown to consist of two 
polypeptide chains, the cr subunit of 53 kDa and 
Correspondence address: F.A. Stephenson, MRC Molecular 
Neurobiology Unit, MRC Centre, Hills Road, Cambridge 
CB2 2QH, England 
* Present address: The Fidia-Georgetown Institute for Neuro- 
sciences, Georgetown University Medical Centre, 3900 Reser- 
voir Road, N.W., Washington, DC 20007, USA 
Abbreviations: GABA, ~,-aminobutyric acid; KLH, keyhole 
limpet haemocyanin; ELISA, enzyme-linked immunoadsorbent 
assay; SDS-PAGE, SDS-polyacrylamide gel electrophoresis; 
TBPS, t-butylbicyclophosphorothionate 
the/3 subunit of 57-58 kDa [2-6] with a molecular 
size of 230-240 kDa [7]. The ce subunit of the 
purified receptor is specifically photoaffinity- 
labelled by the benzodiazepine, [3H]flunitrazepam 
[2,4,8], whereas it is predominantly the/3 subunit 
which is specifically photoaffinity-labelled by the 
GABA agonist, muscimol [9,10]. The primary 
structures of the c~ and/3 subunits have been deduc- 
ed from the corresponding complementary DNAs 
and it was shown that the micro-injection of the ot 
and/3 RNAs into the Xenopus oocyte is sufficient 
to form the GABA-gated C1- channel [11]. 
Extensive photoaffinity-labelling studies with 
[3H]flunitrazepam however, have shown that in 
the membrane-bound form of the receptor from 
several species, multiple polypeptides are specifi- 
cally labelled ([12] and review [1]). This phenome- 
non has been characterised in detail in the rat 
where it was demonstrated that each photolabelled 
subunit has a brain-regional distribution, a pattern 
of post-natal development and a pharmacological 
specificity of labelling [13-15]. Molecular cloning 
studies recently identified 3forms of the tr subunit, 
c~1, or2 and a3, respectively [16]. It was proposed 
that these may form the basis for the above- 
described observations with the rat receptor. We 
here report he identification of the ce3 polypeptide 
in the purified GABAA receptor using antibodies 
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raised against the C-terminal sequence of the 
deduced t~3 primary structure. 
2. MATERIALS AND METHODS 
[N-methyl-3H]Flunitrazepam (85 Ci/mmol), [methyl- 
ene-3H]muscimoi (9 Ci/mmol), biotinylated anti-(rabbit Ig), 
biotinylated anti-(mouse Ig) and streptavidin biotinylated 
peroxidase complex were purchased from Amersham Interna- 
tional (England). Peptide a3 479-492 was purchased from The 
Institute of Animal Physiology, Babraham, Cambridge, 
England. Flunitrazepam and Ro 7-1986/1 were gifts from Dr 
H. Mohler (Hoffman-La Roche, Basel, Switzerland) and 
chlorazepate was a gift from Boehringer lngelheim (Bracknell, 
England). All other materials were as noted elsewhere [3,17]. 
The GABAA receptor was purified from adult bovine cerebral 
cortex, adult bovine cerebellum and 12-day calf cerebral cortex 
by benzodiazepine affinity chromatography s in[3]. GABA 
and benzodiazepine receptor-binding assays, and SDS-PAGE 
under reducing conditions, were carried out as before [3]. 
Western blotting was performed according to [17,18]. 
Peptides Otl 1-15 and at 413-429 and polyclonal ntibodies 
to these peptides were prepared as previously described [18]. 
Peptides al 324-341, sequence PEKPKKVKDPLIKKNNT, 
and or3 479-492 with an additional N-terminal cysteine, se- 
quence CVNRESAIKGMIRKQ, were coupled to keyhole 
limpet haemocyanin (KLH) by either the glutaraldehyde pro- 
cedure (otn 324-341) or via the N-terminal cysteine (or3 
479-492), as described [19]. Peptide-KLH conjugates (0.2/~mol 
peptide) emulsified with Freunds complete adjuvant were in- 
jected at 2 sites intramuscularly into Dutch-belted rabbits (2 
animals per peptide). Subsequent immunisations were in 
Freund's incomplete adjuvant at mon hly intervals. The 
development of the immune response was measured by ELISA 
with the appropriate p ptide or purified GABAA receptor as an- 
tigen, as described [18,20]. 
3. RESULTS AND DISCUSSION 
We have previously shown that polyclonal an- 
tibodies raised against N- and C-terminal se- 
quences of the al subunit of the GABAA receptor 
recognise the receptor in both a native and 
denatured form [18]. Thus, following the 
discovery of the C~l, a~2 and or3 cDNAs we synthe- 
sised a peptide which corresponded to the deduced 
C-terminal amino acid sequence of the ~3 polypep- 
tide. Antibodies to this defined epitope would be 
predicted from our studies as above to react with 
the o~3 subunit if the protein is present in the 
purified receptor p eparations. Antibodies to the 
c~a 479-492 peptide were detected in both rabbits in 
the sera obtained from the first bleed, which was 
made 7 days after the second immunisation. 
Positive antibody titres were obtained on bleed 3 in 
the ELISA assay, with the GABAA receptor 
purified from bovine cerebral cortex as antigen, 
again in both rabbits (not shown). The maximum 
respective antibody titre obtained to date with pep- 
tide as antigen is 1 in 90000 and with adult bovine 
cerebral cortical GABA^ receptor as antigen 1 in 
100. The antibody titre is defined here as the serum 
dilution which gives half the absorbance at492 nm 
in the ELISA as a 1 in 10 dilution of that immune 
serum. 
The anti-~3 479-492 antibodies reacted with 
purified GABAA receptor in Western blots. Fig. 1A 
shows the results of an immunoblot where the 
reactivities of the ~1 and a3 subunit-specific an- 
tibodies with the GABAA receptor purified from 
adult bovine cerebral cortex are compared. It can 
be seen that in all cases, the at subunit-specific an- 
tibodies react predominantly with a polypeptide of 
53 kDa which is coincident with the subunit 
recognised by an anti-native GABA^ receptor an- 
tibody and the anti-GABAA receptor monoclonal 
antibody 1A6. Weak immunoreactivity was also 
observed with a band at 68 kDa for the anti-c~l 
peptide antibodies (fig. 1). This band was also seen 
when non-GABA receptor immune sera were used 
and it was taken thus as a non-specific reaction. 
The anti-a3 479-492 antibodies reacted with a 
polypeptide of 59-60 kDa (fig.l). When high- 
resolution SDS-PAGE was carried out with longer 
gels than previously employed and at low protein 
concentration it was possible to show that the/3 
subunit was resolved into two bands of 57-58 and 
59-60 kDa, respectively (fig. 1B). Previous reports 
had described the/~ suhunit in SDS-PAGE as a 
broad diffuse band [3,4] and this was attributed to 
the possibility that the /~ subunit was heavily 
and/or heterogeneously glycosylated. This ap- 
pearance can now be ascribed to the presence of 
the two polypeptides. 
The deduced primary structure of the ~3 subunit 
predicts a molecular mass of 52 kDa [16]. Within 
the sequence there are four potential N- 
glycosylation sites, the carbohydrate of which 
would contribute towards the size of the a3 subunit 
in SDS-PAGE. It has been demonstrated that the 
c~3 subunit is sensitive to N-glycanase treatment as 
seen by a decrease in the apparent molecular mass 
of the polypeptide after the enzyme treatment of 
approx. 4 kDa (not shown). The molecular mass 
of the core polypeptide then agrees fairly well with 
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Fig.l. (A) Immunoblot with anti-GABAA receptor antibodies. GABAA receptor purified from adult bovine cerebral cortex was 
subjected to SDS-PAGE in 10% polyacrylamide slab gels under reducing conditions. Receptor was transferred to nitrocellulose 
membranes by Western blotting and probed with anti-GABAA receptor antibodies as described in section 2. Each lane corresponds 
to 2.5 pmol [3H] flunitrazepam-binding sites which is approx. 2/~g protein. Antibodies: (l) anti-peptide ~r i 1-15; (2) anti-peptide o~n 
413-429; (3) anti-peptide oq 324-341; (4) anti-peptide ot~ 479-492; (5) anti-native GABAA receptor, t~-subunit specific [17]; (6) 
monoclonal antibody IA6 which at this receptor concentration recognises predominantly the ot subunit [20] and (7) pre-stained protein 
standards with molecular masses as shown. (B) SDS-PAGE of purified bovine cerebral cortical GABAA receptor. GABAA receptor 
was purified from adult bovine cerebral cortex by benzodiazepine affinity chromatography, precipitated with trichloroacetic a id and 
subjected to SDS-PAGE under reducing conditions in 10% polyacrylamide slab gels all as described in [3]. Lanes: (1) silver stain of 
protein standards of molecular masses 93, 66, 45, 21 and 14 kDa; (2) silver stain of GABAA receptor purified from adult bovine 
cerebral cortex. An arrowhead enotes the position of the GABAA receptor subunits. 
the value predicted from the deduced primary 
structure of or3 once account is taken of the 
anomalous hehaviour in SDS-PAGE of membrane 
proteins as seen for the ~rl and fl subunits [11]. In- 
terestingly, Kirkness and Turner [21] have recently 
shown that an anti-or1 101-109 peptide antibody 
reacts with polypeptides of 51 kDa (~r subunit) and 
57 kDa from the GABAA receptor purified from 
porcine cerebral cortex receptor. The reactive band 
at 57 kDa is larger than the ~' subunit identified by 
photoaffinity labelling with [3Hlmuscimol [21]. 
The sequences of the al  and a3 subunits are iden- 
tical in this region in the bovine species. Thus, it is 
conceivable these authors have detected the ~r3 
subunit, identified by us here using an antibody to 
a unique region of the t~3 sequence. 
Previous studies with the rat receptor have 
demonstrated that in adult cerebellum, in contrast 
to other brain regions examined, one polypeptide 
only was predominantly photolabeUed with 
[~H]flunitrazepam [22]. Also, Northern blots using 
isoform-specific oligonucleotide probes have 
shown that the a3 transcript is prominent at an ear- 
ly stage of bovine brain development [16]. Thus, 
we carried out an immunoblot study on the recep- 
tor purified from adult bovine cerebral cortex and 
cerebellum, and 12-day calf cortex. The results are 
shown in fig.2, where it can be seen that the trl and 
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bovine cortex and cerebellum and 12-day calf cor- 
tex. Further work using the specific antibodies 
described herein should permit the quant i tat ion of 
the respective isoforms present in different brain 
regions and perhaps an answer to the question as 
to whether the basis for the type I and II ben- 
zodiazepine receptors can be attr ibuted to the in- 
dividual subunits such as the ~r~ and er3 
polypeptide. 
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